MX360062B - Metodos de elaboracion de fenilacetato de l-ornitina. - Google Patents

Metodos de elaboracion de fenilacetato de l-ornitina.

Info

Publication number
MX360062B
MX360062B MX2013003764A MX2013003764A MX360062B MX 360062 B MX360062 B MX 360062B MX 2013003764 A MX2013003764 A MX 2013003764A MX 2013003764 A MX2013003764 A MX 2013003764A MX 360062 B MX360062 B MX 360062B
Authority
MX
Mexico
Prior art keywords
phenyl acetate
making
methods
ornithine phenyl
ornithine
Prior art date
Application number
MX2013003764A
Other languages
English (en)
Other versions
MX2013003764A (es
Inventor
Behling Jim
Henderson Dougan Christine
William Watt Stephen
Manini Peter
Figini Attilia
H Anderson Keith
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of MX2013003764A publication Critical patent/MX2013003764A/es
Publication of MX360062B publication Critical patent/MX360062B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/32—Phenylacetic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen en la presente los procesos para elaborar el fenilacetato de L-ornitina. El proceso puede incluir por ejemplo, entremezclar una sal de haluro de Lornitina con el fenilacetato de plata. El proceso puede también incluir formar una sal de fenilacetato in situ. La presente solicitud también se refiere a diversas composiciones obtenidas a partir de estos procesos, incluyendo las formas cristalinas.
MX2013003764A 2010-10-06 2011-10-05 Metodos de elaboracion de fenilacetato de l-ornitina. MX360062B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39058510P 2010-10-06 2010-10-06
PCT/US2011/054983 WO2012048043A1 (en) 2010-10-06 2011-10-05 Methods of making l-ornithine phenyl acetate

Publications (2)

Publication Number Publication Date
MX2013003764A MX2013003764A (es) 2013-05-20
MX360062B true MX360062B (es) 2018-10-22

Family

ID=45928120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003764A MX360062B (es) 2010-10-06 2011-10-05 Metodos de elaboracion de fenilacetato de l-ornitina.

Country Status (16)

Country Link
US (2) US8946473B2 (es)
EP (1) EP2625162B1 (es)
JP (1) JP6087284B2 (es)
KR (1) KR101888215B1 (es)
CN (1) CN103502203B (es)
AU (1) AU2011312042B2 (es)
BR (1) BR112013008054B1 (es)
CA (1) CA2813563C (es)
EA (1) EA028395B1 (es)
ES (1) ES2720148T3 (es)
IL (1) IL225512A (es)
MX (1) MX360062B (es)
NZ (1) NZ609191A (es)
SG (1) SG189231A1 (es)
TR (1) TR201903978T4 (es)
WO (1) WO2012048043A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102512408B (zh) 2004-11-26 2015-11-25 Ucl商业有限公司 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸或苯基丁酸的组合物
EP2413924B1 (en) * 2009-04-03 2017-09-27 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CN102625699B (zh) 2009-06-08 2014-08-20 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
EP2625162B1 (en) * 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
CN113633777A (zh) 2014-11-24 2021-11-12 Ucl商业有限公司 使用降氨疗法治疗与肝星状细胞激活相关的疾病
EP4205735A1 (en) * 2015-04-20 2023-07-05 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
CA2995823A1 (en) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
BR112018009349A8 (pt) * 2015-11-13 2019-02-26 Ocera Therapeutics Inc formulações de fenilacetato de l-ornitina
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP7126520B2 (ja) * 2017-05-11 2022-08-26 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンフェニルアセテートを製造する方法
WO2019036471A1 (en) 2017-08-14 2019-02-21 Axcella Health Inc. AMINO ACIDS BRANCHED FOR THE TREATMENT OF LIVER DISEASE
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (es) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
US4100293A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
DE4020980C1 (es) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
AU670627B2 (en) 1992-09-09 1996-07-25 Fisons Plc Pharmaceutical packaging
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) * 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5840891A (en) 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
WO1997030167A1 (en) 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
WO2000071151A1 (fr) 1999-05-21 2000-11-30 Takeda Chemical Industries, Ltd. Regulateurs des fonctions hepatiques
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
ATE441409T1 (de) 2001-03-15 2009-09-15 Riken Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
JPWO2004019928A1 (ja) 2002-08-30 2005-12-15 味の素株式会社 肝疾患治療剤
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) * 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
WO2005082023A2 (en) 2004-02-23 2005-09-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
EP1744770A2 (en) 2004-05-06 2007-01-24 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
EP1799759A1 (en) 2004-08-30 2007-06-27 Lunamed Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
CN102512408B (zh) 2004-11-26 2015-11-25 Ucl商业有限公司 用于治疗肝性脑病的含有鸟氨酸和苯基乙酸或苯基丁酸的组合物
RS53324B (en) 2005-11-17 2014-10-31 Silverstone Pharma Est. STABLE FORMULATION OF AMORPHIC SALES OF PERINDOPRIL, PROCEDURE FOR THEIR PREPARATION, IN PARTICULAR INDUSTRIAL PREPARATION, AND THEIR USE IN HYPERTENSION THERAPY
CN201421432Y (zh) * 2009-02-20 2010-03-10 山东师范大学 一种相干衍射成像处理装置
EP2413924B1 (en) 2009-04-03 2017-09-27 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CN102625699B (zh) 2009-06-08 2014-08-20 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
EP2625162B1 (en) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate

Also Published As

Publication number Publication date
AU2011312042A1 (en) 2013-05-02
US20150133684A1 (en) 2015-05-14
KR20140053807A (ko) 2014-05-08
IL225512A (en) 2017-12-31
NZ609191A (en) 2015-06-26
EP2625162A1 (en) 2013-08-14
US8946473B2 (en) 2015-02-03
JP2013542935A (ja) 2013-11-28
CN103502203A (zh) 2014-01-08
IL225512A0 (en) 2013-06-27
KR101888215B1 (ko) 2018-09-20
EP2625162A4 (en) 2014-06-25
ES2720148T3 (es) 2019-07-18
CA2813563C (en) 2019-02-26
CA2813563A1 (en) 2012-04-12
WO2012048043A1 (en) 2012-04-12
TR201903978T4 (tr) 2019-04-22
CN103502203B (zh) 2016-09-07
BR112013008054A2 (pt) 2016-06-14
EA201390403A1 (ru) 2013-09-30
BR112013008054B1 (pt) 2019-04-09
EP2625162B1 (en) 2019-03-13
MX2013003764A (es) 2013-05-20
SG189231A1 (en) 2013-05-31
JP6087284B2 (ja) 2017-03-01
EA028395B1 (ru) 2017-11-30
US9260379B2 (en) 2016-02-16
US20130211135A1 (en) 2013-08-15
AU2011312042B2 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
MX360062B (es) Metodos de elaboracion de fenilacetato de l-ornitina.
WO2011119004A3 (en) Method of producing d-psicose crystals
EP2762003A4 (en) AGROCHEMICAL COMPOSITION, USES THEREOF AND PROCESS FOR PREPARING THE SAME, AND METHOD FOR GUARANTEEING HIGH PRODUCTIVITY OF CROPS
CA2830549C (en) Methods and compositions for preparing noribogaine from voacangine
EA201291470A1 (ru) Замороженное кондитерское изделие
UA107865C2 (ru) Гетероциклические карбоксамиды
EA033455B1 (ru) Кристаллические формы замещенных 5-фтор-1h-пиразолопиридинов, способы их получения, их применение для получения лекарственного средства, лекарственное средство и способ лечения на их основе
WO2012138147A3 (en) 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid crystalline form and the producing method thereof
EP2563791A4 (en) PROCESS FOR PREPARING A QUATERNARY AMMONIUM SALT USING A PHOSPHATE
SG11201402949RA (en) Process for producing nutrient composition
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
EP2799420A4 (en) PROCESS FOR THE SYNTHESIS OF 2,7-DIMETHYL-2,4,6-OCTATRIENE-1,8-DIALDEHYDE
GEP201606569B (en) Urea finishing method
WO2013168176A3 (en) Process for preparation of fosaprepitant and salt thereof
WO2012140490A3 (en) Processes for preparing pitavastatin calcium
EP2883870B8 (en) Method for producing 1,4-benzoxazine compound
HK1219269A1 (zh) 化合物及其生產方法，以及用於生產磷酸奧司他韋的方法
UA109460C2 (uk) N-гетарилметилпіразолілкарбоксаміди
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
AU2012248013B2 (en) Intermediate for synthesizing caspofungin and preparation method therefor
IL227592A0 (en) A method for making 2,2-difluoroethylamine starting from 2,2-difluoro-1-chloroethane
WO2013072938A3 (en) Process for the preparation of roflumilast
WO2012107445A3 (en) Soft substrate for cell culture and process for preparing the same
WO2012134103A3 (ko) 노보넨 에스터계 유도체, 이의 제조방법 및 이의 용도

Legal Events

Date Code Title Description
FG Grant or registration